ARCHIVES

Fidaxomicin for CDI Therapy More Cost-Effective Than Vancomycin, Study Says

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

Smoker Sues NCI To Compel Guideline For CT Scanning.

January 25, 2008

President Asks $600 Million For NCI In ’75; Research Grants Would Get $19 Million Hike

February 8, 1974

Excerpts Presented From Pepper Hearing

July 20, 1979

Cancer Informatics: NCI Writing Dictionary To Standardize Data Reported In Trials

November 13, 1998

Micafungin Bests Fluconazole In Phase III Antifungal Trial

November 29, 2002

FDA Approves Gilotrif Tablets in NSCLC, Boehringer Ingelheim’s First Approved Cancer Drug

July 26, 2013